PIK3CA and cancer: Despite their improved potency, both ATP-competitive mTOR inhibitors and dual PI3K-mTOR inhibitors fail to fully overcome the resistance mechanisms of classical mTOR inhibitors [199,272], underscoring the complexity of targeting mTOR signalling in cancer therapy.